Companies find their products are best
Industry-sponsored head-to-head statin trials are 20 times more likely to favor the sponsor's drug than a comparator, an article in the June issue of the Public Library of Science states. In an evaluation of 192 randomized controlled trials, Lisa Bero, University of California-San Francisco, et al., also finds that company-sponsored trials are 35 times more likely to reach a conclusion in favor of the sponsor's product. Antipsychotic trials have been found to be similarly biased (1"The Pink Sheet" Feb. 6, 2006, p. 9)...
You may also be interested in...
Clinical trial protocols for head-to-head comparisons of antipsychotic drugs should be reviewed by regulatory authorities like FDA to eliminate potential sources of bias, according to a recent analysis published in the American Journal of Psychiatry
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.